Cassava Sciences shares fall
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease, the Securities and Exchange Commission said on Thursday.
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Stocks to Watch: Cassava Sciences, Scholastic, MeridianLink
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
alzheimersnewstoday15h
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Cassava Sciences Unusual Options Activity For September 23
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...